NCT05233436View on ClinicalTrials.gov

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 24, 2022

Primary Completion Date

October 16, 2023

Study Completion Date

October 16, 2023

Conditions
Advanced Solid TumorsGastric CancerGastroesophageal Junction CancerUrothelial CancerNon Small Cell Lung CancerHead and Neck Squamous Cell Carcinomas
Interventions
DRUG

PF-07265028

PF-07265028 will be administered orally

BIOLOGICAL

Sasanlimab

Administered subcutaneously

Trial Locations (12)

33063

D&H Cancer Research Center LLC, Margate

Napa Research, Margate

49546

START Midwest, Grand Rapids

52242

University of Iowa, Iowa City

75230

Mary Crowley Cancer Research - Medical City Hospital, Dallas

Mary Crowley Cancer Research, Dallas

78229

South Texas Accelerated Research Therapeutics (START), San Antonio

South Texas Accelerated Research Therapeutics, LLC, San Antonio

85258

HonorHealth Research Institute, Scottsdale

85260

HonorHealth Scottsdale Shea Medical Center, Scottsdale

277-8577

National Cancer Center Hospital East, Kashiwa

135-8550

The Cancer Institute Hospital of JFCR, Koto

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05233436 - PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter